"Wolverine" Stack (BPC-157 + TB-500)

Identity not a compound but a combination — the co-administration of two synthetic research peptides, BPC-157 (a 15-amino-acid gastric-juice-derived peptide) and TB-500 (a synthetic fragment of the actin-binding protein Thymosin β4). It's the register's first stack entry, included because it is, by demand, the most popular peptide combination in the healing/recovery space — which makes the gap between its popularity and its evidence the whole point. ## Mechanism (as proposed) the rationale rests on complementary, non-overlapping pathways. BPC-157 acts largely locally: promoting angiogenesis (VEGF/EGF, nitric-oxide pathway), supporting growth-factor signalling, and — in animal tendon/muscle models — accelerating repair; it restores perfusion to injured tissue. TB-500, through Thymosin β4 biology, acts more systemically: its actin-sequestering activity (linked to the Ac-SDKP motif) reduces inflammation and drives migration of endothelial cells, keratinocytes and fibroblasts into the wound bed. The coupling logic is real — new tissue needs both blood supply and mobile repair cells — and because the two don't share rate-limiting steps, they shouldn't compete. But "shouldn't compete" and "demonstrated to work better together" are different claims, and only the first is supported. The interaction — synergistic, merely additive, or neither — has never been measured.